STOCKHOLDERS' EQUITY (Tables)

12 Months Ended

Dec. 31, 2022

Schedule of business acquisitions, by acquisition

Stock issuances in relation to acquisitions during the years ended December 31, 2022, 2021 and 2020 were as follows:


(In millions)	Period of Acquisition	Shares Issued	Fair Value of Shares Issued
OmicEra	May 2022	0.3	$	14.8
PreventionGenetics	December 2021	1.1	84.2
Ashion	April 2021	0.1	16.2
Thrive	January 2021	9.3	1,190.0
Targeted Digital Sequencing (“TARDIS”) license	January 2021	0.2	27.3
Paradigm Diagnostics, Inc. (“Paradigm”) and Viomics, Inc. (“Viomics”)	March 2020	0.4	28.8

The acquisition date fair value of the consideration transferred for OmicEra was approximately $19.4 million, which consisted of the following:


(In thousands)
Common stock issued	$	14,792
Contingent consideration	4,600
Cash paid related to working capital adjustment	16
Total purchase price	$	19,408

The acquisition date fair value of the consideration transferred for PreventionGenetics was approximately $185.4 million, which consisted of the following:


(In thousands)
Cash	$	101,129
Common stock issued	84,252
Total purchase price	$	185,381

The acquisition date fair value of the consideration transferred for Ashion was approximately $110.0 million, which consisted of the following:


(In thousands)
Cash	$	74,775
Common stock issued	16,224
Contingent consideration	19,000
Total purchase price	$	109,999

The acquisition date fair value of the consideration transferred for Thrive was approximately $2.19 billion, which consisted of the following:


(In thousands)
Common stock issued	$	1,175,431
Cash	584,996
Contingent consideration	331,348
Fair value of replaced equity awards	52,245
Previously held equity investment fair value	43,034
Total purchase price	$	2,187,054

Schedule of amounts recognized in accumulated other comprehensive income (loss) (AOCI)

The amount recognized in AOCI for the years ended December 31, 2022, 2021 and 2020 were as follows:


(In thousands)	Cumulative Translation Adjustment		Unrealized Gain (Loss) on Securities		Accumulated Other Comprehensive Income (Loss)
Balance at January 1, 2020	$	(25)	$	(75)	$	(100)
Other comprehensive income before reclassifications	—		771		771
Amounts reclassified from accumulated other comprehensive loss	25		—		25
Net current period change in accumulated other comprehensive loss	25		771		796
Income tax expense related to items of other comprehensive loss	—		(170)		(170)
Balance at December 31, 2020	$	—	$	526	$	526
Other comprehensive income (loss) before reclassifications	23		(1,648)		(1,625)
Amounts reclassified from accumulated other comprehensive loss	—		(514)		(514)
Net current period change in accumulated other comprehensive loss	23		(2,162)		(2,139)
Income tax benefit related to items of other comprehensive loss	—		170		170
Balance at December 31, 2021	$	23	$	(1,466)	$	(1,443)
Other comprehensive income (loss) before reclassifications	30		(4,049)		(4,019)
Amounts reclassified from accumulated other comprehensive loss	—		226		226
Net current period change in accumulated other comprehensive loss	30		(3,823)		(3,793)
Balance at December 31, 2022	$	53	$	(5,289)	$	(5,236)

_________________________________

(1)There was no tax impact from the amounts recognized in AOCI for the year ended December 31, 2022.

Schedule of amounts reclassified from accumulated other comprehensive income (loss)

Amounts reclassified from AOCI for the years ended December 31, 2022, 2021 and 2020 were as follows:


		Year Ended December 31,
Details about AOCI Components (In thousands)	Affected Line Item in the Statements of Operations	2022		2021		2020
Change in value of available-for-sale investments
Sales and maturities of available-for-sale investments	Investment income	$	226	$	(514)	$	—
Foreign currency adjustment	General and administrative	—		—		25
Total reclassifications		$	226	$	(514)	$	25